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Determinants of Mortality After Myocardial Infarction in Patients
With Advanced Renal Dysfunction
John N. Beattie, MD, Sandeep S. Soman, MD, Keisha R. Sandberg, BS, Jerry Yee, MD,
Steven Borzak, MD, Mukesh Garg, MD, and Peter A. McCullough, MD, MPH
● Previous studies using administrative data have shown high mortality in patients with renal failure requiring
dialysis after acute myocardial infarction (AMI). There has been little investigation into the mortality after AMI in
those with advanced renal disease who are not on dialysis therapy. We analyzed a prospective coronary care unit
registry of 1,724 patients with ST segment elevation myocardial infarction admitted over an 8-year period at a single
tertiary-care center. Those not on chronic dialysis therapy were stratified into groups based on corrected creatinine
clearance, with cutoff values of 46.2, 63.1, and 81.5 mL/min/72 kg. Dialysis patients (n ⴝ 47) were considered as a
fifth comparison group. Older age, black race, diabetes, hypertension, previous coronary disease, and heart failure
were incrementally more common across increasing renal dysfunction strata. There were also graded increases in
the relative risk for atrial and ventricular arrhythmias, heart block, asystole, development of pulmonary congestion,
acute mitral regurgitation, and cardiogenic shock. Primary angioplasty, thrombolysis, and ␤-blockers were used
less often across the risk strata (P < 0.0001 for all trends). There was an early mortality hazard (age-adjusted relative
risk, 8.76; P < 0.0001) for those with renal dysfunction but not on dialysis therapy for the first 60 months, followed
by graded decrements in survival across increasing renal dysfunction strata. The excess mortality in this
population appears to be mediated through arrhythmias, adverse hemodynamic events, and the lower use of
mortality-reducing therapy.
© 2001 by the National Kidney Foundation, Inc.
INDEX WORDS: Coronary care unit; renal failure; survival; arrhythmias; complications.

A

DVANCED RENAL FAILURE requiring dialysis has been established as an independent predictor of mortality after acute myocardial infarction (AMI).1-4 It has also been suggested
that lesser degrees of renal failure, measured as
serum creatinine (Cr) and blood urea nitrogen
(BUN)l levels or corrected creatinine clearance
(CorrCrCl), predict survival in patients with acute
coronary syndromes, AMI, and after a variety of
cardiovascular events.2-8 However, knowledge of
the determinants of mortality in these patient
populations has been limited by previously used
data collection methods and the routine exclusion of these patients from most large randomized AMI trials. Accordingly, we sought to evaluate the independent determinants of AMI
mortality across the full spectrum of renal dysfunction.
METHODS

Setting, Data Collection, and Follow-Up
Henry Ford Hospital is a 903-bed tertiary care center
located in Detroit, MI. The hospital receives patients whose
care is provided primarily within the Henry Ford Health
System, a vertically integrated, mixed-model, managed care
organization with an advanced information technology infrastructure.9,10 Methods of data collection used in the Henry
Ford Hospital Cardiac Intensive Care Unit Database have
been previously described.11 In brief, this is a registry in
which every admission to a 16-bed unit had clinical data

(⬃250 discrete elements) prospectively recorded on case
report forms by trained research assistants. Data collected
from May 1, 1990, to August 22, 1998, included baseline
demographics, laboratory values, and events occurring during the unit stay, such as revascularization and complications. The data collection period was stopped after discharge
from the unit, either to another floor or to home.
Mortality during the unit stay was recorded prospectively.
On an annual basis, vital status was tracked by ascertainment
of future activity in the health system, confirmation of death
by identification matching with the State of Michigan Death
Certificate Registry, or record of a death on a later hospitalization within the health system corporate data stores. Finally, for those not identified with any of these means, the
available Internet death identification service (www.ancestry.
com) was used to confirm death primarily in a state other
than Michigan. These data strategies yielded a 99% overall
vital status ascertainment rate for patients followed up after
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the first admission longitudinally over 27 ⫾ 28 months
(minimum, 0 months; maximum, 100 months). The subset of
1,724 patients reported here from the 9,544-patient parent
database was selected on the basis of the case report form
indicating an ST segment elevation AMI defined as characteristic chest pain and ST segment elevation of 1 mm or
greater in two or more contiguous leads on the initial
electrocardiogram (ECG).

Assessment of Baseline Renal Function
The database was augmented with merged data from
laboratory tables to obtain complete renal function data,
taken as the initial admission serum Cr level in millgrams
per deciliter, for 9,544 patients (99.9%). Because weight was
not available in the database, CorrCrCl was used as the best
measure of baseline renal function as follows12-15:
CorrCrCl male ⫽ (140 ⫺ age y )/72
CorrCrCl female ⫽ 0.85[(140 ⫺ age y )/72]
CorrCrCl was found to be unimodal and normally distributed. Other epidemiological measures of renal function were
considered, including 1/Cr and those formulas derived from
patients without diabetes by Levey et al.15 Given the advantages of correcting for age and sex, the high rates of diabetes
in our population, and the performance of this measure in the
parent database, which is substantially larger than that of
previous studies, it was decided to retain CorrCrCl as the
measure of interest.11 Therefore, all 9,544 patients were
divided into quartiles at the cutoff values of 46.2, 63.1, and
81.5 mL/min/72 kg. Quartile analysis of CorrCrCl was
favored as an epidemiological tool over modeling CorrCrCl
as a continuous variable because it allowed for analysis of
trends by group and inclusion of dialysis patients. Patients
on chronic dialysis therapy (n ⫽ 527) again were considered
as a fifth comparison group. From this parent database,
1,723 consecutive patients with ST segment elevation AMI
were evaluated on this study according to the strata of renal
dysfunction described previously. We previously published
the validation of 11 arrhythmic, hemodynamic, and fatal
outcomes by blinded chart abstraction in which the mean
percentage of agreement was 92.7% across the 11 outcomes.11

Statistical Analysis
Baseline characteristics are reported as mean ⫾ SD or
proportions with 95% confidence intervals (CIs), as appropriate, with exclusion of missing data points. Univariate comparisons were performed using analysis of variance or chisquare, as appropriate. Chi-square test for linear trend was
used for comparisons of baseline characteristics across ascending levels of renal dysfunction. Multiple logistic regression was performed for the outcome of in-hospital death,
with independent odds ratios (ORs) reported with 95% CIs.
All models were tested for interactions. Variables in the
causal pathway were included in the final models. Cox
proportional hazards model was used to derive the independent hazard of estimated renal function with cumulative

long-term survival. The log-rank test was used to evaluate
the independent differences in survival across the strata. All
P are two-tailed and considered significant at ␣ less than
0.05.

RESULTS

Baseline Characteristics
Table 1 lists baseline characteristics of the
patient groups stratified by renal risk. Overall
mean age was 63.4 ⫾ 13.8 years (range, 15 to 98
years). The mean age for women and men was
similar at 63.6 ⫾ 13.8 and 63.3 ⫾ 13.7 years,
respectively (P ⫽ 0.22). The overall womanman ratio was 0.73, with men predominant in all
groups. For the study group, 1,037 patients
(60.1%) were white, 629 patients (36.5%) were
black, and 57 patients (3.3%) were categorized
as “other race.” Black race increased in proportion from groups 1 to 4, but accounted for a
smaller percentage of patients on dialysis therapy
(40.4% versus 53.2%). Diabetes and hypertension were more common across the ascending
risk groups 1 to 5 (P ⬍ 0.0001 for both trends).
Conversely, smoking and hyperlipidemia were
more common in the lower renal risk groups
(P ⬍ 0.0001 for both trends). Previous coronary
artery disease increased over the renal strata
from 21.4% to 40.9% for a history of angina and
16% to 27.9% for a previous AMI (P ⬍ 0.0001
for both). Rates of prior coronary revascularization were similar among the groups. A history of
congestive heart failure (CHF) also increased in
frequency from 5.3% to 31.7% when comparing
groups 1 to 5 (P ⬍ 0.0001). Rates of CHF
medications, including angiotensin-converting
enzyme inhibitors, diuretics, and digoxin, also
increased over the strata, consistent with the
frequencies of diabetes, CHF, and hypertension
observed.
Admission Clinical Findings
Physical examination findings and baseline
laboratory values are listed in Table 2. Patients
were more likely to be admitted with CHF with
the expected physical examination findings of an
S3, rales, and peripheral edema across the strata
of increasing renal dysfunction. The clinical diagnosis of CHF and physical examination findings
were separate variables on the case report form.

AMI MORTALITY IN RENAL DISEASE
Table 1.
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Baseline Clinical Characteristics of 1,724 Patients Admitted to a Coronary Care Unit With ST Segment
Elevation Myocardial Infarction Stratified by Renal Risk Group

Characteristic

No. of patients
Age (y)
Women-men ratio
Black
White
Other race
Diabetes
Hypertension
Dyslipidemia
Tobacco use
Prior angina
Prior AMI
Any prior
revascularization
Prior CHF
Aspirin
␤-blockers
ACE inhibitor
Calcium channel
blockers
Nitrates
Diuretics
Digitalis

Group 1
CorrCrCl* ⬎ 81.5
mL/min/72 kg

Group 2 63.1 ⬍
CorrCrCl ⱕ 81.5
mL/min/72 kg

Group 3 46.2 ⬍
CorrCrCl ⱕ 63.1
mL/min/72 kg

Group 4
CorrCrCl ⱕ 46.2
mL/min/72 kg
Not on Dialysis

524
54.4 ⫾ 13.0
0.52
153 (29.2)
353 (67.4)
18 (3.4)
124 (23.7)
269 (51.3)
205 (39.1)
345 (65.8)
109 (21.4)
82 (16.0)

421
62.8 ⫾ 12.2
0.48
149 (35.4)
255 (60.6)
17 (4.0)
111 (26.4)
228 (54.2)
150 (35.6)
248 (58.9)
101 (24.6)
89 (21.9)

421
69.8 ⫾ 11.8
0.58
160 (38.0)
252 (59.9)
9 (2.1)
124 (29.5)
252 (59.9)
149 (35.4)
222 (52.7)
115 (28.0)
93 (22.4)

310
70.2 ⫾ 12.9
0.76
148 (47.7)
152 (49.0)
10 (3.2)
118 (38.1)
235 (75.8)
103 (33.2)
158 (51.0)
100 (34.0)
103 (34.7)

58 (11.1)
27 (5.3)
149 (30.0)
88 (17.6)
61 (12.3)

35 (8.3)
29 (7.2)
124 (31.2)
86 (21.3)
60 (15.3)

40 (9.5)
32 (7.9)
123 (30.8)
85 (21.0)
65 (16.3)

33 (10.6)
69 (23.2)
76 (27.7)
53 (19.2)
71 (25.3)

7 (14.9)
13 (31.7)
15 (39.5)
8 (20.5)
8 (20.5)

0.43
0.84
⬍0.0001 ⬍0.0001
0.22
0.99
0.65
0.45
0.14
⬍0.0001

98 (19.6)
67 (13.5)
62 (12.4)
15 (3.0)

77 (19.4)
67 (16.6)
56 (14.2)
18 (4.6)

74 (18.6)
91 (22.6)
85 (21.1)
28 (7.0)

88 (31.5)
73 (26.0)
97 (33.9)
40 (14.2)

14 (35.0)
18 (45.0)
22 (51.2)
10 (25.0)

0.02
⬍0.0001
⬍0.0001
⬍0.0001

Group 5
Chronic
Dialysis

P Group 1
v Group 5

P for
Trend

47
—
—
64.9 ⫾ 16.2 ⬍0.0001 ⬍0.0001
0.34
19 (40.4)
⬍0.0001 ⬍0.0001
25 (53.2)
0.0001 ⬍0.0001
3 (6.4)
0.53
0.27
19 (40.4)
0.01
⬍0.0001
30 (63.8)
0.10
0.23
11 (23.4)
0.03
0.02
28 (59.6)
0.001
⬍0.0001
18 (40.9)
0.003
⬍0.0001
12 (27.9)
0.05
⬍0.0001

⬍0.0001
⬍0.0001
⬍0.0001
⬍0.0001

NOTE. Only the first admission is counted in these comparisons. Values in parentheses are percentages.
Abbreviations: PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass graft surgery;
ACE, angiotensin-converting enzyme.

They showed significant clustering, thus supporting the diagnosis. There were increasing levels
of blood pressure and heart rate across the renal
risk strata. In addition, there were greater rates of
atrial fibrillation, complete heart block, and left
bundle-branch block on the admission ECG
across the renal risk strata. Patients with advanced renal dysfunction were more likely to
have a combination of infarct locations, including anteroseptal, lateral, and posterior walls (P ⬍
0.0001). There was no difference in mean peak
creatine kinase levels measured from groups 1 to
5 (mean creatine kinase: group 1, 1,917.6 ⫾
1,740.3 U/L; group 5, 1,715.6 ⫾ 1,636.3 U/L;
P ⫽ 0.23). Evidence for left ventricular dysfunction was more common in the higher renal risk
strata; the majority of those in groups 4 and 5 had
cardiomegaly on initial chest radiograph. Cardiomegaly was more than twice as common a radiographic finding in the highest versus lowest renal

dysfunction group (group 1, 22.9%; group 5,
58.6%; P ⬍ 0.0001).
Arrhythmic and Hemodynamic Complications
Table 3 lists the graded increases in univariate
risk for developing atrial fibrillation, ventricular
tachycardia, and ventricular fibrillation across
the renal risk strata. There was a clear doseresponse relation seen between level of renal
dysfunction and development of complete heart
block (Table 3). Table 3 lists univariate risks for
hemodynamic complications occurring from the
time of emergency department presentation
through the coronary care unit course. These
complications were defined on the case report
form as having developed after hospital arrival,
based on the clinical examination and supportive
diagnostic testing. For example, acute mitral
regurgitation was defined as the presence of a
new or worsened murmur and the finding of new
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Table 2. Physical Examination and ECG Findings and Laboratory Values for 1,724 Patients Admitted
to a Coronary Care Unit With ST Segment Elevation AMI Stratified by Renal Risk Group

Group 1
CorrCrCl ⬎
81.5 mL/min/
72 kg

No. of patients
Physical examination
findings
Heart rate
(beats/min)
SBP (mm Hg)
DBP (mm Hg)
Jugular venous
distension (%)
Pulmonary rales
S3
S4
Hepatomegaly
Peripheral edema
Infarct location by ECG
Anteroseptal
Anterior
Inferior
Lateral
High lateral
Posterior
LBBB
Combination
Other ECG findings
Atrial
fibrillation/flutter
Complete heart
block
Laboratory values
Sodium (mEq/L)
Potassium (mEq/L)
Hemoglobin (g/dL)
Creatinine (mg/dL)*
BUN (mg/dL)†

Group 2 63.1 ⬍ Group 3 46.2 ⬍
CorrCrCl ⱕ
CorrCrCl ⱕ
81.5 mL/min/
63.1 mL/min/
72 kg
72 kg

Group 4
CorrCrCl ⱕ
46.2 mL/min/
72 kg Not on
Dialysis

Group 5
Chronic
Dialysis

P Group 1
v Group 5

P for
Trend

310

47

—

—

0.003
0.17
0.27

⬍0.0001
0.02
0.77

524

421

421

80.9 ⫾ 18.6
126.8 ⫾ 22.6
74.4 ⫾ 15.5

83.0 ⫾ 19.8
129.0 ⫾ 24.2
76.1 ⫾ 16.1

83.0 ⫾ 21.6
130.6 ⫾ 26.1
76.4 ⫾ 15.8

87.1 ⫾ 22.0
84.6 ⫾ 22.0
130.4 ⫾ 28.7 131.6 ⫾ 3.7
74.3 ⫾ 18.4
74.6 ⫾ 22.7

34/508 (6.7)
61/507 (12.0)
37/507 (7.3)
79/507 (15.6)
10/501 (2.0)
26/500 (5.2)

38/406 (9.4)
69/406 (17.0)
49/405 (12.1)
81/405 (20.0)
8/403 (2.0)
32/404 (7.9)

38/412 (9.2)
90/413 (21.8)
41/412 (10.0)
88/410 (21.5)
5/410 (1.2)
32/410 (7.8)

45/293 (15.4)
93/204 (31.3)
50/287 (17.4)
53/288 (18.4)
12/288 (4.2)
46/287 (16.0)

9/43 (20.9)
18/45 (40.0)
10/43 (23.3)
7/42 (16.7)
3/44 (6.8)
7/44 (15.9)

⬍0.0001
⬍0.0001
⬍0.0001
0.21
0.03
⬍0.0001

⬍0.0001
⬍0.0001
⬍0.0001
0.21
0.05
⬍0.0001

115 (21.9)
53 (10.1)
170 (32.4)
47 (9.0)
22 (4.2)
42 (8.0)
3 (0.6)
0 (0.0)

109 (25.9)
57 (13.5)
157 (37.3)
50 (11.9)
31 (7.4)
26 (6.2)
8 (1.9)
17 (4.0)

100 (23.8)
44 (10.5)
191 (45.4)
44 (5.23)
23 (5.5)
34 (8.1)
7 (1.7)
22 (5.2)

84 (27.1)
37 (11.9)
116 (37.4)
51 (16.5)
21 (6.8)
22 (7.9)
12 (3.9)
33 (10.6)

14 (29.8)
7 (14.9)
14 (29.8)
13 (27.7)
9 (19.1)
4 (8.5)
2 (4.3)
17 (36.1)

0.21
0.44
0.71
0.0002
⬍0.0001
0.87
0.99
⬍0.0001

⬍0.0001
0.35
0.37
⬍0.0001
⬍0.0001
⬍0.0001
0.01
⬍0.0001

32 (6.1)

30 (7.1)

37 (8.8)

50 (16.1)

5 (10.6)

⬍0.0001

0.74

6 (1.1)

15 (3.6)

23 (5.5)

19 (6.1)

3 (6.4)

0.0001

0.72

137.7 ⫾ 5.8
4.2 ⫾ 0.9
13.6 ⫾ 2.0
0.8 ⫾ 0.2
16.2 ⫾ 18.3

138.0 ⫾ 5.0
4.1 ⫾ 0.7
13.7 ⫾ 1.9
1.0 ⫾ 0.2
16.0 ⫾ 9.9

137.8 ⫾ 5.9
4.2 ⫾ 0.7
13.4 ⫾ 2.1
1.2 ⫾ 0.2
21.8 ⫾ 24.5

136.9 ⫾ 5.0
138.6 ⫾ 7.7
0.21
0.37
4.4 ⫾ 0.9
4.5 ⫾ 1.0
0.001
0.001
12.7 ⫾ 2.3
12.2 ⫾ 2.7 ⬍0.0001 ⬍0.0001
2.7 ⫾ 2.6
3.3 ⫾ 2.5 ⬍0.0001 ⬍0.0001
28.5 ⫾ 23.5
40.1 ⫾ 25.2 ⬍0.0001 ⬍0.0001

NOTE. Values in parentheses are percentages.
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; LBBB, left bundle-branch block.
*To convert to micromolar, multiply by 88.4.
†To convert to millimolar, multiply by 0.357.

or worsened mitral regurgitant flow on echocardiography. Likewise, new pulmonary edema was
defined as the development of rales and/or a
consistent chest radiograph with pulmonary
edema. Cardiogenic shock was defined as hypotension (systolic blood pressure ⬍ 90 mm Hg or
mean arterial pressure ⬍ 70 mm Hg) and inadequate perfusion attributable to a cardiac cause.
In a graded fashion, group 5 had the greatest

adjusted risk for developing acute mitral regurgitation, pulmonary edema, and cardiogenic shock
compared with group 1.
Treatment Received
Unless there was an absolute contraindication,
all patients were administered 162 mg of soluble
aspirin according to the coronary care unit AMI
admission orders. Figure 1 shows the decreasing

AMI MORTALITY IN RENAL DISEASE
Table 3.
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Risks for Arrhythmic and Hemodynamic Complications Stratified by Renal Risk Group

No.
Atrial fibrillation or atrial flutter
OR
95% CI
P
Sustained ventricular tachycardia
OR
95% CI
P
Ventricular fibrillation
OR
95% CI
P
Complete heart block
OR
95% CI
P
Asystole
OR
95% CI
P
Pulmonary edema
OR
95% CI
P
Acute mitral regurgitation
OR
95% CI
P
Cardiogenic shock
OR
95% CI
P

Group 1
CorrCrCl ⬎ 81.5
mL/min/72 kg

Group 2 63.1 ⬍
CorrCrCl ⱕ 81.5
mL/min/72 kg

Group 3 46.2 ⬍
CorrCrCl ⱕ 63.1
mL/min/72 kg

Group 4 CorrCrCl ⱕ
46.2 mL/min/72 kg
Not on Dialysis

Group 5
Chronic
Dialysis

524

421

421

310

47

1.00
—
—

1.18
0.71-1.98
0.53

1.48
0.91-2.42
0.12

2.96
1.85-4.72
⬍0.0001

1.83
0.68-4.95
0.22

1.00
—
—

1.60
0.81-3.20
0.18

1.34
0.66-2.74
0.42

2.21
1.11-4.43
0.02

2.31
0.65-8.30
0.18

1.00
—
—

2.35
1.25-4.39
0.006

1.92
1.01-3.66
0.05

4.17
2.27-7.65
⬍0.0001

2.95
0.95-9.22
0.07

1.00
—
—

3.19
1.23-8.29
0.01

4.99
2.01-12.37
⬍0.0001

5.64
2.23-14.27
⬍0.0001

5.88
1.42-24.34
0.03

1.00
—
—

7.31
2.13-25.11
⬍0.0001

5.10
1.43-18.18
0.007

15.23
4.56-50.90
⬍0.0001

11.84
2.32-60.41
0.009

1.00
—
—

1.51
1.08-2.10
0.02

1.79
1.30-2.48
⬍0.0001

3.36
2.41-4.67
⬍0.0001

4.41
2.37-8.23
⬍0.0001

1.00
—
—

3.57
1.28-10.00
0.02

3.84
1.38-10.62
0.006

3.81
1.31-11.10
0.02

7.08
1.64-30.60
0.02

1.00
—
—

1.48
0.85-2.56
0.20

1.87
1.10-3.16
0.02

3.57
2.15-5.93
⬍0.0001

4.09
1.73-9.68
0.003

NOTE. Unadjusted odds ratios with 95% CIs and number per cell are given with Group 1 as the referent.
Abbreviation: OR, odds ratio.

rates of treatment with reperfusion (angioplasty
or thrombolysis) and ␤-blocker use across the
renal risk strata (P ⬍ 0.0001 for all trends). Of
note, angioplasty proportions include primary
angioplasty and treatment for failure of thrombolysis and recurrent ischemia after medical therapy.
Additionally, 44 patients (2.6%) underwent coronary artery bypass surgery during the coronary
care unit stay.
In-Hospital Death and Long-Term Survival
Figure 2 shows age- and sex-adjusted risks for
in-hospital death stratified by renal risk group.
Of note, those in group 4 with advanced renal
dysfunction but not on dialysis therapy had the

greatest risk for in-hospital death (age-adjusted
relative risk, 8.76; P ⬍ 0.0001). Figure 3 shows
the adjusted relative hazard for cumulative death
over long-term follow-up. Groups 3 through 5
had worsened survival compared with groups 1
and 2 (P ⬍ 0.05 by log rank). Group 4 had the
worst survival for the first 60 months until its
survival curve was crossed by group 5, patients
on chronic dialysis therapy, who showed an
overall mortality rate of 60% during the follow-up period.
DISCUSSION

This study has shown that baseline renal function, measured as CorrCrCl in milliliters per
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Fig 1. Treatment received
for AMI stratified by renal
dysfunction group. (䊐) Angioplasty; ( ) thrombolysis;
(■) beta blockers.

minute per 72 kg, accurately stratifies patients
entering the coronary care unit with an AMI with
respect to in-hospital complications and longterm survival. Through a range of normal serum
Cr levels, 0.8 ⫾ 0.2 mg/dL (70.7 ⫾ 17.7 mol/L)
to 1.2 ⫾ 0.2 mg/dL (106.1 ⫾ 17.7 mol/L) in
groups 1 through 3, there are measurable graded
increases in risk. At the highest level of renal
dysfunction not yet requiring dialysis (Cr, 2.7 ⫾
2.6 mg/dL [238.1 ⫾ 229.3 mol/L]), the risk
appears to be the greatest for several adverse
outcomes.
There were significant ethnic differences across
the renal risk groups, with a greater proportion of
blacks in the higher risk groups, including 40.4%
of those on chronic dialysis therapy compared

Fig 2. Age- and sex-adjusted risks for in-hospital
death in 1,724 patients admitted to a coronary care unit
with ST segment elevation
AMI stratified by renal risk
group. For groups 2 through
5, P < 0.0001.

with 29.2% of those in the lowest risk group. The
impact of baseline comorbidities across the renal
strata was evident. Those patients on chronic
dialysis therapy had, as expected, significantly
greater rates of diabetes, hypertension, and CHF.
Measurement of left ventricular function was not
performed routinely on patients. However, when
it was assessable by such indices as cardiothoracic ratio, it was lower in the higher risk strata,
consistent with greater rates of prior CHF.
Our study found the rates of mortality-reducing therapy, including angioplasty, thrombolysis,
and ␤-blocker use, were all reduced at progressively lower levels of renal function. This indicates a treatment bias in favor of those with less
baseline comorbidity and is consistent with the
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Fig 3. Survival analysis of
1,724 consecutive patients
admitted to a coronary care
unit stratified by baseline serum Cr level. Proportional
hazards have been adjusted
for age and sex. The overall
model found CorrCrCl statistically significant (P <
0.0001). This shows an early
mortality hazard within 5
years after discharge for individuals with CorrCrCl of
46.2 mL/min/72 kg or less but
not on dialysis therapy
(group 4) compared with
those on dialysis therapy
(group 5). P < 0.05 for comparisons of groups 3 through
5 versus 1 and 2.

findings of other investigators.1 The reduced rates
of percutaneous intervention (15.2% of those
with CorrCrCl ⬍ 46.2 mL/min/72 kg) can be
understood in light of the increased risk for
contrast nephropathy and its related mortality.5
However, the lower rates of thrombolysis and
␤-blocker use can only be partially explained by
increased rates of hemodynamic complications.
This implies that considerable progress can be
made in AMI mortality by the extension of
reperfusion and ␤-blockers to those with advanced renal dysfunction.16
This study suggests other unmeasured intermediate factors are present that mediate risk for
arrhythmias, hemodynamic problems, and death.
Candidate biological and clinical mechanisms
include the presence of LVH, diastolic dysfunction, volume overload, adverse pharmacological
interactions, endothelial dysfunction, and more
aggressive atherosclerosis related to increases in
serum homocysteine level.17-20 The increases in
hypertension and ECG voltage criteria for left
ventricular hypertrophy (LVH) seen across the
strata are suggestive that left ventricular mass
index, although poorly correlated with ECG LVH,
if measured, would be more common in the
higher risk groups.21-23 Evidence from the literature exists to expect a high rate of LVH in the
predialysis and dialysis populations.24 In these

groups, LVH has been related to greater rates of
asymptomatic ventricular arrhythmias, stroke, and
cardiac events, including AMI, revascularization, CHF, and cardiac death.25-28 Diastolic dysfunction commonly occurs in patients with endstage renal disease with LVH and is a likely
mechanism for the development of pulmonary
edema.29,30 Volume overload is anticipated in
groups 4 and 5, with the distinct possibility that
the volume excess is better handled by dialysis
than high-dose diuretics in those with significant
impairment in renal function. This may explain
in part the plateau in risk seen in group 4 for
many of the adverse outcomes. Adverse drug
interactions, or at least more problematic administration of such commonly used drugs as digitalis, diuretics, angiotensin II–converting enzyme inhibitors, and antiarrhythmics, would be
expected in groups 4 and 5 and may have contributed to poor outcomes.
Several lines of evidence suggest that worsened renal clearance is associated with endothelial dysfunction, which probably has a role in the
development of pulmonary edema.31,32 However,
it is not known which process is first, cardiac or
renal dysfunction, as the inciting factor for endothelial dysfunction. It has been hypothesized that
the candidate factor related to a more aggressive
coronary atherosclerotic diathesis in patients with
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renal failure is homocysteine. Serum homocysteine level has been found to track with levels of
serum creatinine and BUN and be markedly
elevated in those on chronic dialysis therapy.33-35
Recent data from stable patients and those with
acute coronary syndromes suggest graded increases in risk for future cardiac events through
the range of normal serum homocysteine levels.36,37 Other putative atherosclerosis risk factors in patients with renal failure include elevations of serum fibrinogen and lipoprotein(a)
levels.38 In addition, there are undoubtedly hundreds of factors, including advanced glycation
and lipoxidation end products in patients with
renal failure, that may have a role in atherogenesis, but these are in the early stages of scientific
investigation.39,40
We found an early hazard with respect to
survival for those with reduced CorrCrCl less
than 46.2 mL/min/72 kg but not yet on dialysis
therapy. This suggests that dialysis therapy,
whether by selection or biological action, has at
least a stabilizing effect on mortality in the first 5
years after discharge. Our observed mortality
rate at 2 years of 65.0% was consistent with the
results recently reported by Herzog et al41 from
the US Renal Data System.
Like all retrospective studies of prospectively
collected data, our study is subject to the threats
to validity posed by missing data. In addition, the
single measure of renal function, initial serum Cr
level, undoubtedly was influenced by the degree
of hydration, renal perfusion, and, in some cases,
possibly acute renal failure. Ejection fraction
was not captured in the data registry; however, it
is expected that lower mean ejection fractions
would have been recorded in the higher renal
dysfunction strata consistent with the rates of
prior CHF and in-hospital hemodynamic complications. Outpatient medications were not captured in the data collection; thus, the influence of
lipid-reducing agents, aspirin, ␤-blockers, and
angiotensin-converting enzyme inhibitors were
not taken into account after hospital discharge.
The initiation of dialysis therapy also was not
captured in our registry. We expect this was rare
and may have influenced group 4, a predialysis
group, but not the other groups, in which new
dialysis was an unlikely clinical issue.5,6
In-hospital mortality rates do not reflect deaths
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in the emergency department or in patients who
were transferred to long-term care facilities with
the intent of terminal care. In addition, we did
not capture the advanced directives of patients in
the database; therefore, variation in the frequency and determinants of in-hospital mortality
are inherent in this study.
The results of this study are more applicable to
urban tertiary hospitals with greater proportions
of blacks and the expected comorbidities of
diabetes, hypertension, and CHF. Practice settings and clinical trials that care for and include
primarily lower risk patients may not be able to
replicate the important relationship between renal dysfunction and outcomes observed in this
study.
This study points out four fundamental mechanisms for the observed cardiorenal risk: (1) uncontrolled confounding, (2) therapeutic nihilism,
(3) adverse effects of conventional therapy, and
(4) special biological processes. Mechanisms 2
through 4 should be systematically approached
from a clinical and research standpoint. Clearly,
the more equitable use of proven therapies should
be a goal of those treating patients with AMI and
renal dysfunction. The safety and efficacy of
reperfusion and antithrombotic therapy in those
with renal dysfunction should be systematically
addressed with randomized trials. Last, the special biological effects of the renal dysfunction
state on the pathogenesis of atherosclerosis, heart
failure, arrhythmias, and conduction disturbances should be studied in great detail given the
generalizability to our aging US population.
In conclusion, baseline CorrCrCl derived from
serum Cr level, age, and sex is a significant
independent risk factor for acute arrhythmic and
hemodynamic complications after AMI. Furthermore, renal risk stratification can identify groups
with high rates of in-hospital death and poor
long-term survival. This risk is only partially
explained by such comorbidities as diabetes, age,
CHF, and treatment received. We conclude that
renal function is integrally related to survival
after a variety of cardiac events and that further
research into the clinical and biological mechanisms for this relation are warranted.
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